Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial | Zendy

Run Dong | Zendy; Li Jiang | Zendy; Ting Yang | Zendy; Changsong Wang | Zendy; Yi Zhang | Zendy; Xu Chen | Zendy; Jianfeng Xie | Zendy; Yuanbin Guo | Zendy; Li Weng | Zendy; Yan Kang | Zendy; Kaijiang Yu | Zendy; Haibo Qiu | Zendy; Bin Du | Zendy

Open Access

Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial

Author(s) -

Run Dong,

Li Jiang,

Ting Yang,

Changsong Wang,

Yi Zhang,

Xu Chen,

Jianfeng Xie,

Yuanbin Guo,

Li Weng,

Yan Kang,

Kaijiang Yu,

Haibo Qiu,

Bin Du

Publication year - 2022

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02045-21

Subject(s) - medicine , adverse effect , randomized controlled trial , odds ratio , randomization , confidence interval , clinical trial , clinical endpoint

Recombinant human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibody JS016 showed neutralizing and therapeutic effects in preclinical studies. The clinical efficacy and safety of the therapy needed to be evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research